Description

Boston Scientific Is Buying Penumbra—But the Real Story Is What Comes Next!

If you’re wondering what Boston Scientific has been up to lately, buckle up. On January 15, the medtech heavyweight announced it would acquire Penumbra for a staggering $15 billion in a cash-and-stock deal, offering $374 per share. That represents a 19% premium over Penumbra’s last close. This isn’t just any acquisition—it’s the company’s biggest move since the $25 billion Guidant buyout two decades ago. The goal? Expanding Boston Scientific’s reach in the fast-growing fields of mechanical thrombectomy and neurovascular intervention. With Penumbra’s innovative portfolio and global presence, this deal could serve as a springboard for Boston Scientific’s long-range financial goals. While the transaction is expected to close sometime in 2026, the implications are already sending ripples through the medical device world. The Boston Scientific Penumbra acquisition may reshape not only the company’s product map, but also its long-term revenue growth, operating margins, and global presence.